Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
22.85
Aug 03 • 5:02 AM ET Dollar change-2.15 Percentage change(-8.60%)
Jul 31, 1:01 PMApnimed (APMD) surges on strong Nasdaq debut after upsized $192M IPO
Index
-
Market Cap
868.30M
Enterprise Value
1.11B
Income
-
Sales
-
Book/sh
-8.00
Cash/sh
1.23
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Jul 31, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
18.52
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.82
Current Ratio
1.82
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / No
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
-69.75% -
Sales past 3/5Y
237.57% -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-4.49%
SMA50
-4.49%
SMA200
-4.49%
Trades
Shs Outstand
38.00M
Shs Float
-
52W High
29.15 -21.61%
52W Low
16.12 41.75%
Volatility
- -
ATR (14)
7.69
RSI (14)
-
Beta
-
Rel Volume
0.01
Avg Volume
3.44M
Volume
1,769
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
Perf YTD
3.86%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
25.00
Price
22.85
Change
-8.60%
Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.
CEO & DirectorMr. Kevin R. Lind
M.P.H.Dr. Lawrence G. Miller M.D.
President & COOMr. Dennis P. Molnar M.B.A.
Senior Manager of AdministrationMs. Leila Sylvain
Ph.D.Dr. Sean M. Johnston M.B.A.